Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same

• US 8,034,346 B2
• Filed: 12/22/2009
• Issued: 10/11/2011
• Est. Priority Date: 02/19/2003
• Status: Expired due to Fees

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Inventors: Vergara, German J., Loo, Carole M., Shelton, David L.
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US12/644,087
• Publication Number:
  US 20100143355A1
• Time in Patent Office: 658 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.

Claims

1. A method for treating pain in an individual comprising administering to the individual an effective amount of an anti-nerve growth factor (NGF) antibody and an NSAID, whereby the anti-NGF antibody and the NSAID in conjunction provide effective pain relief, wherein the anti-NGF antibody comprises a heavy chain variable region comprising:

(i) a CDR1 having the sequence 5′

GFSLIGYDLN 3′

(SEQ ID NO;

3),

(ii) a CDR2 having the sequence 5′

IIWGDGTTDYNSAVKS 3′

(SEQ ID NO;

4), and

(iii) a CDR3 having the sequence 5′

GGYWYATSYYFDY 3′

(SEQ ID NO;

5),

and

wherein the anti-NGF antibody comprises a light chain variable region comprising;

(i) a CDR1 having the sequence 5′

RASQSISNNLN 3′

(SEQ ID NO;

6),

(ii) a CDR2 having the sequence 5′

YTSRFHS 3′

(SEQ ID NO;

7), and

(iii) a CDR3 having the sequence 5′

QQEHTLPYT 3′

(SEQ ID NO;

8).

2. The method of claim 1, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, naprosyn, diclofenac, ketoprofen, tolmetin, sulindac, mefanamic acid, meclofenamic acid, diflunisal, flufenisal, piroxicam, sudoxicam, isoxicam, celecoxib, fofecoxib, DUP-697, flosulide, meloxicam, 6-methoxy-2-naphthylacetic acid, MK-966, nabumetone, nimesulide, NS-398, SC-5766, SC-58215 and T-614.

3. The method of claim 1, wherein the NSAID is ibuprofen.

4. The method of claim 1, wherein the anti-NGF antibody binds human NGF.

5. The method of claim 4, wherein the anti-NGF antibody binds human NGF with a binding affinity of about 10 nM or less than about 10 nM.

6. The method of claim 4, wherein the pain is post-surgical pain.

7. The method of claim 1, wherein the pain is post-surgical pain.

8. The method of claim 1, wherein the anti-NGF antibody and the NSAID in conjunction provide a greater effect in treating pain than the corresponding amount of NSAID alone.

9. The method of claim 1, wherein the individual is a human.

10. The method of claim 1, wherein the anti-NGF antibody is a monoclonal antibody.

11. The method of claim 10, wherein the monoclonal antibody is a humanized antibody, a human antibody, a chimeric antibody, a bispecific antibody or an antibody fragment, wherein the antibody fragment is Fab, Fab′

, (Fab′

)₂, Fv fragments, diabodies, single chain antibody molecules, multispecific antibodies, or a single-chain Fv molecule.

12. The method of claim 10, wherein the monoclonal antibody is E3.